Radioactive
Liver metastases
Pancreatic cancer
Permanent implantation
Radioactive 125I seeds
Radiotherapy
Therapeutic effect
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
06 Feb 2021
06 Feb 2021
Historique:
received:
16
11
2020
revised:
03
12
2020
accepted:
11
12
2020
entrez:
15
2
2021
pubmed:
16
2
2021
medline:
16
2
2021
Statut:
ppublish
Résumé
Preoperative diagnosis rate of pancreatic cancer has increased year by year. The prognosis of pancreatic cancer patients with unexpected liver metastasis found by intraoperative exploration is very poor, and there is no effective and unified treatment strategy. To evaluate the therapeutic effect of radioactive The demographics and perioperative outcomes of patients who underwent Preoperative imaging evaluation of all patients in this study showed that the tumor was resectable without liver metastasis. There were 26 patients in this study, including 18 males and 8 females, aged 60.5 ± 9.7 years. The most common tumor site was the pancreatic head (17, 65.4%), followed by the pancreatic neck and body (6, 23.2%) and pancreatic tail (3, 11.4%). Fourteen patients (53.8%) underwent palliative surgery and postoperative pain relief occurred in 22 patients (84.6%). The estimated blood loss in operation was 148.3 ± 282.1 mL and one patient received blood transfusion. The postoperative hospital stay was 7.6 ± 2.8 d. One patient had biliary fistula, one had pancreatic fistula, and all recovered after conservative treatment. After operation, 7 patients received chemotherapy and 19 did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not (68.6% Radioactive
Sections du résumé
BACKGROUND
BACKGROUND
Preoperative diagnosis rate of pancreatic cancer has increased year by year. The prognosis of pancreatic cancer patients with unexpected liver metastasis found by intraoperative exploration is very poor, and there is no effective and unified treatment strategy.
AIM
OBJECTIVE
To evaluate the therapeutic effect of radioactive
METHODS
METHODS
The demographics and perioperative outcomes of patients who underwent
RESULTS
RESULTS
Preoperative imaging evaluation of all patients in this study showed that the tumor was resectable without liver metastasis. There were 26 patients in this study, including 18 males and 8 females, aged 60.5 ± 9.7 years. The most common tumor site was the pancreatic head (17, 65.4%), followed by the pancreatic neck and body (6, 23.2%) and pancreatic tail (3, 11.4%). Fourteen patients (53.8%) underwent palliative surgery and postoperative pain relief occurred in 22 patients (84.6%). The estimated blood loss in operation was 148.3 ± 282.1 mL and one patient received blood transfusion. The postoperative hospital stay was 7.6 ± 2.8 d. One patient had biliary fistula, one had pancreatic fistula, and all recovered after conservative treatment. After operation, 7 patients received chemotherapy and 19 did not. The 1-year survival rate was significantly higher in patients who received chemotherapy than in those who did not (68.6%
CONCLUSION
CONCLUSIONS
Radioactive
Identifiants
pubmed: 33585625
doi: 10.12998/wjcc.v9.i4.792
pmc: PMC7852643
doi:
Types de publication
Journal Article
Langues
eng
Pagination
792-800Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare no conflicts of interest related to this article.
Références
J Cancer Res Ther. 2019;15(4):818-824
pubmed: 31436237
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Zhonghua Wai Ke Za Zhi. 2020 Jan 1;58(1):22-26
pubmed: 31902165
J Gastrointest Oncol. 2019 Dec;10(6):1080-1093
pubmed: 31949925
Health Equity. 2019 Oct 29;3(1):532-540
pubmed: 31663065
J Cancer Res Ther. 2018;14(7):1455-1462
pubmed: 30589023
Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):559-63
pubmed: 9112453
Expert Opin Ther Targets. 2018 Nov;22(11):955-966
pubmed: 30244621
Ann Surg Oncol. 2018 Apr;25(4):1043-1051
pubmed: 29302820
Chin J Cancer. 2013 Jun;32(6):334-41
pubmed: 22958741
Anticancer Res. 2020 Jan;40(1):293-298
pubmed: 31892579
World J Gastrointest Surg. 2019 Jul 27;11(7):303-307
pubmed: 31602289
Pancreatology. 2019 Oct;19(7):941-950
pubmed: 31447281
J Gastrointest Oncol. 2019 Aug;10(4):663-673
pubmed: 31392047
Surg Endosc. 2019 Feb;33(2):658-662
pubmed: 30374794
Int J Radiat Biol. 2019 May;95(5):571-579
pubmed: 30557072
Pancreas (Fairfax). 2019;3(1):9-14
pubmed: 31930185
J Cancer Res Ther. 2019;15(7):1553-1560
pubmed: 31939437
J Interv Gastroenterol. 2011 Jan;1(1):23-27
pubmed: 21686109
J Cancer Res Ther. 2019;15(7):1567-1573
pubmed: 31939439
Clin Colorectal Cancer. 2016 Dec;15(4):360-368
pubmed: 27262896
Int J Clin Exp Pathol. 2015 Sep 01;8(9):11218-23
pubmed: 26617845
World J Gastroenterol. 2013 Oct 14;19(38):6479-84
pubmed: 24151368